Human Papilloma Virus Vaccine Awareness and Vaccination History in Patients Attending STI Clinics in Lagos and Ibadan, Nigeria
HPV is one of the most common causes of sexually transmitted disease in both men and women worldwide. It is transmitted through vaginal, anal, and oral sex. HPV can spread with or without visible warts in developing countries, cervical cancer is often the most common cancer in women and may constitute up to 25% of all female cancers. HPV has been found in 99.7 % of cervical carcinomas worldwide with HPV 16 and 18 being the predominant genotype in these carcinomas (de Sanjose et al 2007). The study provided information on the Human Papilloma Virus (HPV) vaccine awareness and vaccination history in relation to the level of antibodies to (HPV) in the population at risk
Patients attending STI clinics at Lagos and Ibadan were accessed and informed consent was obtained from all the participants of this study. Using semi structured questionnaire, vaccination history, demography and past experiences of the patients were obtained. Whole blood samples were obtained and the sera screened for specific antibodies to HPV using ELISA test kits for determination of IgG to HPV by DIA PRO Diagnostic Bioprobes Milano-Italy according to the manufacturer’s instruction. Of the one hundred and seventy samples analysed 50 (29.4%) samples were positive for HPV, 30 (17.6%) of which are females and 20 (11.7%) are males.Thirty five (35%) of the 100 women who filled the questionnaires were aware of HPV vaccine. 15(15%) women did not take the vaccine because they did not know where to get it while twenty (20%) women could not afford it. It was also noted that there is higher prevalence among the middle aged women. A high prevalence of HPV antibodies was observed in the study yet none of the participants had received the HPV vaccine thus the antibodies is from infection Implication is that the 30 women who tested positive for the HPV antibodies are at risk of cervical cancer
Barbisan, G., Pérez, L.O., Contreras, A. Golijow C. D. 2012 Tumor Biol. (2012) 33: 1549. doi:10.1007/s13277-012-0408-1
Cogliano, V. et al., 2005. Carcinogenicity of human papillomaviruses. Lancet Oncology, 6(4), p.204.
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur, Hausen H. 2004. Classification of papillomavirusses: Virology: 324:17-27 de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. 2007. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 7:453-9.
Hwang SG, Lee D, Kim J, Seo T, Choe J. 2002. Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J Biol Chem;277(4):2923–30
Howley PM, Lowy DR. Papillomaviruses. 2003. In: Knipe DM, Howley PM, editors. Fields Virology. 5th Ed. Philadelphia: Lippincott, Williams &Wilkins; 2007. pp. 2299–2354.Burd E. M.
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (2007). TNF-α and IL-10 promoter polymorphisms, HPV infection,and cervical cancer riskRecommendations of the Advisory Committee on Immunization Practices(ACIP). QuadrivalentHuman Papillomavirus Vaccine. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 6;348(6):518-27.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GMHuman.2007.Papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.Int J Cancer. 1;121(3):621-32.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189: 12–19|
Thomas Hiller, Sven Poppelreuther, Frank Stubenrauch. 2006. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiology Biomarkers and Prevention: 15:1262-1267
Vaccarella S, Franceschi S, Clifford G.M, Touzé A, Hsu C.C, de Sanjosé S, Anh P T H, Hieu N. T, Matos E, Hai Rim Shin H. R, Sukvirach S, Thomas J.O, Boursaghin L, Gaitan J, Snijders P. J. F, Meijer C, Muñoz N, Herrero R, Pierre Coursaget P and for the IARC HPV Prevalence Surveys Study Group. 2014. Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiology, Biomarkers & Prevention 19 (9), 2379-2388.9
Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, Sherman ME, Rodriguez AC, Castle PE, Morales J, Alfaro M, Wright T, Chen S, Clayman B, Burk RD, Viscidi RP. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer. 2003;89:1248–1254.